Cathal Friel, chief executive of Venn Life Sciences Holdings plc (LON:VENN) and founder of spoke to Proactive London's Andrew Scott following a general meeting to approve the merger of the two companies.
Friel, a co-founder of (), former chairman of Fastnet Oil & Gas for five years, and now chief executive of Venn, set up Open Orphan two years ago.
He and his team want to grow the company into a full-service consultancy for orphan and rare disease drugs.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Open Orphan named herein, including the promotion by the Company of Open Orphan in any Content on the Site, the Company receives from said...
FOR OUR FULL DISCLAIMER CLICK HERE